Article

Nutrition a priority for dry eye patients

Author(s):

Julianne Mobilian
Conferences|ASCRS

Here's why John Sheppard, MD, believes nutrition should be the cornerstone of dry eye therapy.

John Sheppard, MD, discusses the benefits of supplementing nutraceuticals with other treatments to improve dry eye symptoms at the annual 2019 ASCRS meeting in San Diego. 

RELATED: Lid hygiene device improves meibomian gland dysfunction, blepharitis

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Related Content
Palatin releases updated results from responder analyses of phase 3 Melody-1 trial in dry eye
April 29th 2025

Palatin releases updated results from responder analyses of phase 3 Melody-1 trial in dry eye

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Characteristics of dry eye disease in patients with autoimmune diseases
April 23rd 2025

Characteristics of dry eye disease in patients with autoimmune diseases

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Zhaoke enrolls first patient in phase 3 trial of cyclosporine ophthalmic gel for dry eye
April 20th 2025

Zhaoke enrolls first patient in phase 3 trial of cyclosporine ophthalmic gel for dry eye

Harrow expands VEVYE Access for All program to Klarity-C patients
April 11th 2025

Harrow expands VEVYE Access for All program to Klarity-C patients

© 2025 MJH Life Sciences

All rights reserved.